Minimum Investment
About Company
Company Name: Q-Line Biotech Limited
Industry / Sector: In-Vitro Diagnostics (IVD) / Diagnostic Reagents & Equipment
Founded Year: 2010
Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty, Abhay Agrawal
Q-Line Biotech Limited is a leading Indian manufacturer and marketer of In-Vitro Diagnostic (IVD) products. The company develops, manufactures, and supplies a wide range of diagnostic reagents, kits, Point-of-Care (POC) devices, consumables, and diagnostic equipment. Its portfolio covers Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Rapid Tests. The company serves hospitals, diagnostic labs, medical colleges, and pathology centres across India.
IPO Basic Details
| Company Name | Q-Line Biotech Limited |
| IPO Type | SME IPO |
| Price Band | ₹326 – ₹343 |
| Lot Size | 400 |
| Total Issue Size | ₹214.48 Cr (62,53,200 shares) |
IPO Strengths & Risks
Strengths
- Indigenous manufacturing with strong R&D
- Wide product portfolio across multiple segments
- Established distribution network
- Quality certifications and regulatory compliance
- Experienced promoters with deep domain knowledge
Risks
- Regulatory changes in diagnostics sector
- Intense competition from multinational players
- Dependence on imports for some raw materials
IPO Important Dates
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Demat Credit Date | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Anchor Investor Date | - |
| UPI Mandate Deadline | - |
IPO Objectives
- Capital expenditure for machinery and equipment – -
- Funding working capital requirements – -
- Debt repayment – -
- General corporate purposes – Balance amount
Investor Reservation
| QIB Quota | 49.99% (incl. Anchor) |
| Retail Quota | 35.00% |
| HNI Quota | - |
| Employee Quota | - |
| Shareholder Quota | - |
| Anchor Investor Allocation | - |
Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 lots | 800 | ₹2,74,400 |
| Retail Maximum | - | - | - |
| S-HNI Minimum | 3 lots | 1200 | ₹4,11,600 |
| S-HNI Maximum | - | - | - |
| B-HNI Minimum | 8 lots | 3200 | ₹10,97,600 |
Key Performance Indicators (KPI)
| ROE | 16.88% (31 Dec 2025) / 17.66% (31 Mar 2025) |
| ROCE | 13.32% (31 Dec 2025) / 23.74% (31 Mar 2025) |
| RoNW | - |
| PAT Margin | 16.65% (31 Dec 2025) / 8.97% (31 Mar 2025) |
| EBITDA Margin | 27.64% (31 Dec 2025) / 22.73% (31 Mar 2025) |
| EPS | - |
| NAV per share | - |
| Debt to Equity | 1.06 (31 Dec 2025) / 0.87 (31 Mar 2025) |
| P/E Ratio | - |
| Industry P/E | - |
Company Financial Data
| Period | Assets | Total Income | PAT | EBITDA | Net Worth | Borrowings |
|---|---|---|---|---|---|---|
| 31 Mar 2023 | 251.58 Cr | 184.81 Cr | 32.10 Cr | 32.98 Cr | 127.37 Cr | 73.65 Cr |
| 31 Mar 2024 | 339.25 Cr | 206.45 Cr | 34.44 Cr | 37.63 Cr | 161.81 Cr | 96.91 Cr |
| 31 Mar 2025 | 455.49 Cr | 322.58 Cr | 28.13 Cr | 71.32 Cr | 189.95 Cr | 164.95 Cr |
| 31 Dec 2025 | 561.34 Cr | 236.50 Cr | 38.69 Cr | 64.23 Cr | 229.04 Cr | 243.85 Cr |
Grey Market Premium
| GMP Price | ₹63 (approx 18.37%) |
| Kostak Rate | N/A |
| Subject to Sauda | N/A |
| Last Updated | 20 May 2026 |
| Estimated Listing Price | ₹406 – ₹410 |
IPO Subscription Data
| Total Subscription | Pending (IPO opens 21 May 2026) |
| QIB (Ex Anchor) | Pending |
| HNI Subscription | Pending |
| Retail Subscription | Pending |
| Anchor | - |
IPO Intermediaries
Registrar: Purva Sharegistry (India) Pvt. Ltd.
Registrar Website: https://www.purvashare.com
IPO Lead Manager(s)
Company Information
Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh 226012
Website: https://qlinebiotech.com/
Email: compliance@qlinebiotech.com
Phone: +91 522-2435570
IPO Documents
Frequently Asked Questions (FAQ)
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.